title: Acute in vivo exposure to interferon-gamma enables resident brain dendritic cells to become effective antigen presenting cells.
abstract: Dendritic cells (DC) are the professional antigen presenting cells (APC) that bridge the innate and adaptive immune system. Previously, in a CD11c/EYFP transgenic mouse developed to study DC functions, we anatomically mapped and phenotypically characterized a discrete population of EYFP(+) cells within the microglia that we termed brain dendritic cells (bDC). In this study, we advanced our knowledge of the function of these cells in the CD11c/EYFP transgenic mouse and its chimeras, using acute stimuli of stereotaxically inoculated IFNgamma or IL-4 into the CNS. The administration of IFNgamma increased the number of EYFP(+)bDC but did not recruit peripheral DC into the CNS. IFNgamma, but not IL-4, upregulated the expression levels of major histocompatibility class II (MHC-II). In addition, IFNgamma-activated EYFP(+)bDC induced antigen-specific naïve CD4 T cells to proliferate and secrete Th1/Th17 cytokines. Activated bDC were also able to stimulate naïve CD8 T cells. Collectively, these data reveal the Th1 cytokine IFNgamma, but not the Th2 cytokine IL4, induces bDC to up-regulate MHC-II and become competent APC.
authors.affiliation: Laboratory of Neuroendocrinology, The Rockefeller University, New York, NY 10065, USA.
authors.forename: Andres
authors.initials: A
authors.lastname: Gottfried-Blackmore
authors.forename: Ulrike W
authors.initials: UW
authors.lastname: Kaunzner
authors.forename: Juliana
authors.initials: J
authors.lastname: Idoyaga
authors.forename: Jennifer C
authors.initials: JC
authors.lastname: Felger
authors.forename: Bruce S
authors.initials: BS
authors.lastname: McEwen
authors.forename: Karen
authors.initials: K
authors.lastname: Bulloch
mesh_terms: D000818:Animals; D000938:Antigen-Presenting Cells / Q000187:drug effects* / Q000276:immunology*; D001426:Bacterial Proteins / Q000378:metabolism; D001921:Brain / Q000166:cytology*; D039521:CD11c Antigen / Q000378:metabolism; D015496:CD4-Positive T-Lymphocytes / Q000166:cytology / Q000187:drug effects / Q000276:immunology; D002454:Cell Differentiation / Q000187:drug effects; D002465:Cell Movement / Q000187:drug effects; D003713:Dendritic Cells / Q000166:cytology / Q000187:drug effects / Q000276:immunology*; D000939:Epitopes / Q000187:drug effects; D000949:Histocompatibility Antigens Class II / Q000276:immunology; D007371:Interferon-gamma / Q000008:administration & dosage / Q000494:pharmacology*; D015847:Interleukin-4 / Q000494:pharmacology; D008164:Luminescent Proteins / Q000378:metabolism; D008213:Lymphocyte Activation / Q000187:drug effects; D051379:Mice; D008810:Mice, Inbred C57BL; D011836:Radiation Tolerance / Q000187:drug effects; D054400:Receptors, CCR7 / Q000378:metabolism
chemical_list: D001426:Bacterial Proteins; D039521:CD11c Antigen; C515371:Ccr7 protein, mouse; D000939:Epitopes; D000949:Histocompatibility Antigens Class II; D008164:Luminescent Proteins; D054400:Receptors, CCR7; C054562:yellow fluorescent protein, Bacteria; D015847:Interleukin-4; D007371:Interferon-gamma